Latest fund size
$54.7M
Announced
November 4, 2026
Global HQ
Singapore
Members only
Check size
$2M-$5M
Members only
Stage focus
Pre-Seed, Seed
Members only
Regions of investment
Asia, USA
Members only
NeoSci Ventures (NSV) is a Singapore-based biotech venture builder founded by Daphne Teo and Dr. Timothy Lu, investing in therapeutics and scientific tools at the intersection of biology, AI, and data.
Daphne Teo, Founding Managing Partner
Fiona Lee, Assistant Vice President
Dr. Timothy Lu, Founding Chief Scientist
Members only
Names, roles, emails and LinkedIn profiles for the team, plus the fund's website.
NeoSci Ventures (NSV) is a Singapore-based biotech venture builder investing in therapeutics and tools at the intersection of biology, AI, data, and scientific research.
The firm identifies scientific opportunities and builds companies around them from the ground up, often taking founder, board, or executive roles in a company's early years.
NSV also sources drug assets from Asian biotech companies that could help global pharmaceutical groups refill their pipelines, investing across Singapore, Taiwan, and the United States.
Members only
What the fund looks for in founders and which sectors it backs.
NeoSci Ventures raised a $54.7 million first close for its inaugural institutional venture fund, targeting up to 12 portfolio companies.
Backers include Taiwan's National Development Fund, EDBI, Catcher Technology, and Crescendas Group, alongside other sovereign and government-linked institutions, listed companies, family offices, and entrepreneurs.
Members only
Fund size, LPs and track record.
Leadership
Daphne Teo – Founding Managing Partner (also CEO & Founder of NSG BioLabs)
Dr. Timothy Lu – Founding Chief Scientist (MIT professor and co-founder/CEO of Senti Biosciences)
The team is also supported by venture partners and senior advisers.
Investment Strategy
NSV runs a hands-on venture-building model, identifying scientific opportunities and building companies around them with direct operational support from inception.
The firm's leadership has spent 15 years building and investing in biotech, with portfolio companies collectively raising billions of dollars and reaching 10 public listings and acquisitions.
Notable Investments
Notable Exits
Enleofen Bio's platform and products were acquired by Boehringer Ingelheim in a deal that could exceed $1 billion per product. Tango Therapeutics is Nasdaq-listed with a valuation above $3 billion.
Members only
Leadership, investment strategy, notable investments and exits.
